Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1738]

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural...

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

KATHERINE trial updates for HER2-positive breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of...

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Role of molecular diagnostics in prostate cancer

Dr Elena Castro and Dr Shahneen Sandhu

Role of molecular diagnostics in prostate cancer ( Dr Elena Castro and Dr Shahneen Sandhu )

Bladder cancer: Latest advances in targeted therapies and precision medicine...

Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and...

Bladder cancer: Latest advances in targeted therapies and precision medicine from ESMO 2019 ( Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr Michiel Van der Heijden )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Real-world use of carfilzomib therapy among patients with existing...

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

Continuous treatment versus fixed duration therapy: Using real-world evidence...

Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )

Public policy in the fight against non-communicable diseases

Dr Tabaré Vazquez - President of Uruguay

Public policy in the fight against non-communicable diseases ( Dr Tabaré Vazquez - President of Uruguay )

More from ecancer